Podium to Practice: Chicago 2025 – BREAST: VERITAC-2

Podium to Practice: Chicago 2025 – BREAST: VERITAC-2

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Christine Simmons

Icon Chair Speaker

Speakers

Dr. Christine Brezden-Masley

Dr. Heather McArthur

Studies / Trials Discussed

LBA1000 – Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.

This program has been made possible through unrestricted support from Eli Lilly.

Studies/trials discussed:

LBA1000 – Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
Tagged